70 results about "Tuberculosis diagnosis" patented technology

The invention discloses a fluorescence PCR quick diagnosis reagent box of the zoonosis tuberculosis, which belongs to the biological technology field. A group of nucleotide sequence for detecting the zoonosis tuberculosis is the nucleotide sequence shown from the sequence table SEQ ID No.1 to the sequence table SEQ ID No.12. The content disclosed by the invention comprises a fluorescence PCR primer and a probe sequence for a mycobacterium tuberculosis composite group, mycobacterium tuberculosis, cow mycobacterium and fowl mycobacterium, a fluorescence PCR reaction system, a detection program, a reaction parameter and a judging method of various reagent boxes, and the preliminary treatment and the nucleic acid extraction method of various clinic samples of bacteria fluid, milk sample, blood sample, sputum, fecal sample and lymph nodes. The invention provides diagnosis reagent for the zoonosis tuberculosis diagnosis of which the technology method is special, sensitive and quick and the quality is reliable. The adoption of the reagent box provided by the invention can accomplish the whole process from the sample treatment to the fluorescence PCR detection within a day, and the detection sensitivity can reach the single gene copy or the signal bacterial cell.

The present invention relates to a gamma-interferon sandwich ELISA detection method based on recombinant fusion antigen protein, further relates to a recombinant fusion antigen protein preparation method and a gamma-interferon monoclonal antibody preparation method, and belongs to the technical field of medical examination determination. According to the present invention, the recombinant fusion antigen protein is formed by linking secretory antigen protein MPB70, antigen protein CFP10 and antigen protein ESAT6 through peptide bonds, the gamma-interferon monoclonal antibody is prepared through immunization of animals, cell fusion, hybridoma cell screening, cloning and purification, and the recombinant fusion antigen protein and the gamma-interferon monoclonal antibody are adopted to establish a sandwich ELISA detection method; and the recombinant fusion antigen protein can rapidly stimulate a bovine blood sample to secret gamma-interferon, and the gamma-interferon monoclonal antibody can quickly and specifically identify bovine gamma-interferon, such that strong sensitivity and strong specificity are provided, and broad application prospects are provided in the field of buffalo tuberculosis diagnosis.

The invention discloses a mycobacterium tuberculosis surface lipolysaccharide-antistatic nucleic acid aptamer and application thereof. The aptamer is a small molecular single-stranded deoxyribonucleic acid (ssDNA) which is specific to toxic mycobacterium tuberculosis surface lipolysaccharide ManLAM (Mannosylated Lipoarabinomannan) and has tuberculosis infection resisting and cellular immunity enhancing functions, and the nucleotide sequence of the ssDNA is shown as SEQIDNo.1. The small molecular ssDNA has a novel target spot and a novel structure which are different from those of the conventional anti-tuberculosis medicament, and has the immunologic suppression function of directly enclosing the ManLAM. The aptamer is easy to prepare and has low price; the obtained ssDNA aptamer is specifically combined on the surface of toxic mycobacterium tuberculosis; and the treatment targeting is further enhanced. The problems of increasing medicament tolerance and large side effect existing in the conventional treatment of tuberculosis are solved, and the aptamer can be taken as an effective novel anti-tuberculosis medicament or a tuberculosis diagnosis reagent.

The invention discloses mycobacterium tuberculosis ESAT6 serial recombinant fusion protein and application thereof. The invention provides a mycobacterium tuberculosis ESAT6 codon optimization method, a serial recombinant fusion method and a method for preparing the fusion protein, and also provides a method for manufacturing and applying the recombinant fusion protein in a whole-blood IFN-gamma tuberculosis diagnosis kit and a TCELL-SPOT tuberculosis infection diagnosis kit. The fusion protein has the advantages of high specificity, high sensitivity and the like, and the requirements of the tuberculosis (TB) infection clinical diagnosis are well met.

The invention discloses an oligonucleotides aptamer of targeted mycobacterium tuberculosis Ag85B, a preparation method and application thereof. The oligonucleotides aptamer has nucleotide sequences shown as AP-1 to AP-13. The preparation method of the oligonucleotides aptamer comprises steps as follows: (1) constructing a random single-stranded DNA (ssDNA) library and preparing a primer; (2) preparing the random single-stranded DNA (ssDNA) library by PCR amplification; (3) carrying out SELEX screening; (4) detecting the appetency; (5) cloning and sequencing DNA. The oligonucleotides aptamer of targeted mycobacterium tuberculosis Ag85B is applied to detect the antigen level of the mycobacterium tuberculosis Ag85B in human serum, can replace antibodies, improves the sensitivity and the specificity of the tuberculosis antigen detection in specimens of body fluid (such as serum, hydrothorax, cerebrospinal fluid ascites and the like), thereby improving the accuracy rate of tuberculosis diagnosis.

The present invention relates to a DNA aptamer binding specifically to tuberculosis specific antigen 7.7 kDa (TB7.7), a biosensor for diagnosis of tuberculosis, comprising the same, and a method for providing information for diagnosis of tuberculosis. The present inventors found that not only does a DNA aptamer according to the present invention have specific binding potential to TB7.7 protein, but also the binding affinity is excellent. When used, the DNA aptamer of the present invention can be thus expected to exhibit greater stability than a conventional ELISA method using an antibody. Hence, the aptamer is expected to find useful applications in the development of compositions for tuberculosis diagnosis, biosensors for tuberculosis diagnosis, and information providing methods for tuberculosis diagnosis.

The invention discloses microRNA biomarkers related to tuberculosis, and particularly provides a kit for tuberculosis detection. The biomarkers include microRNA (ribonucleic acid) 451a, microRNA542, microRNA125b, microRNA146a, microRNA29c, microRNA365, microRNA889, microRNA335 and microRNA342. Quantitative detection of the microRNA biomarkers can be achieved according to technologies such as nucleic acid chips, qPCR (quantitative polymerase chain reaction) or sequencing, so that the kit can be used for clinically auxiliary tuberculosis diagnosis or therapeutic outcome evaluation, sensitivity and specificity of tuberculosis diagnosis are improved, and the new basis is provided for clinical treatment evaluation.

The invention belongs to the fields of biochemistry and immunology, relates to a protein and a kit for tuberculosis diagnosis, and particularly relates to a separated protein shown as the following amino acid sequence SEQ ID NO:1 or SEQ ID NO:2. The protein can be used as a molecular marker for cell-level tuberculosis immunodiagnosis, and has a good accordance rate and intensity of reaction.

The invention discloses preparation for Rv2645 protein, and the application thereof on aspects of tuberculosis diagnosis and recombination BCG vaccines. According to the preparation for Rv2645 protein and the application thereof, the Rv2645 protein in a tuberculosis gene RD10-14 zone is found to have the ability of inducing high-level gamma interferon, and when used for the diagnosis of the serum antibodies, especially IgG4 subtype antibodies, of a tuberculosis patient, has prominent statistics difference compared with the serum antibodies of healthy people; as the dominant antigen of the mycobacterium tuberculosis, the Rv2645 protein has the function of inducing high-level cellular immunity and humoral immunity, and can be used as a novel diagnostic reagent for tuberculosis; the Rv2645 protein can further be used for novel recombination BCG vaccines or protein vaccines for tuberculosis, the constructed recombination BCG capable of expressing the Rv2645 protein has the function of antituberculous immunity protection. According to the preparation for the Rv2645 protein and the application thereof provided by the invention, the Rv2645 protein is proved to have potential application value when used for tuberculosis diagnosis and reorganized BCG vaccines, so that the preparation and the application thereof has significant economic benefits.

Disclosed are methods and devices for analyzing aerosol particles in exhaled breath using diagnostic tools that enable rapid, low cost and autonomous point of care assays for several diseases including respiratory tract diseases. Disclosed are methods and devices for capturing exhaled breath aerosols in a packed bed column and analyzing exhaled captured breath aerosols for tuberculosis diagnosis.

The invention discloses a kit and primer pair combinations for distinguishing active tuberculosis patients and non-tuberculous pneumonia patients. The primer pair combinations include SEQ ID NO:1-2, SEQ ID NO:3-4 and SEQ ID NO:5-6, wherein the SEQ ID NO:1-2 corresponds to a CD157 gene, the SEQ ID NO:3-4 corresponds to an IL-1b gene, and the SEQ ID NO:5-6 corresponds to an MS4A6A gene. By adoptionof the primers for RT-PCR expansion and substitution of related gene expression level into an established formula, the active tuberculosis patients and the non-tuberculous pneumonia patients can be distinguished, and accuracy and quickness in tuberculosis diagnosis are realized.

The invention belongs to the field of biological medicines, and relates to an application of a molecular marker CLEC2B in tuberculosis diagnosis. The invention provides an application of a reagent fordetecting the expression level of the molecular marker CLEC2B in preparation of a kit for diagnosing tuberculosis.

The invention belongs to the biochemistry and immunology fields, relates to a protein and medicine composition used for tuberculosis diagnosis, and concretely relates to a separation protein. The amino acid sequence of the protein is shown in SEQ ID NO:1 or SEQ ID NO:2. The protein can be used as a molecular marker or a vaccine candidate for tuberculosis immunologic diagnosis in cellular level and has a good coincidence rate and reaction intensity.

The invention discloses an application of hsa-miR-378i as a marker molecule to preparation of a tuberculosis diagnosis reagent kit and a detection reagent kit for tuberculosis diagnosis. The hsa-miR-378i is from a plasma exosome, and the base sequence of the hsa-miR-378i is shown as SEQID NO:1. The detection reagent kit contains a detection reagent for specially detecting the marker molecule. Besides, the invention further discloses an application to preparation the tuberculosis diagnosis reagent kit through union of hsa-miR-378i and one or two of hsa-miR-148a-3p and hsa-miR-150-5p as the marker molecule. Experimental result indicates that hsa-miR-378i has high specificity, sensitivity and diagnosis effects on tuberculosis diagnosis. Therefore, the application has great application prospects and market prospects to the field of tuberculosis diagnosis.

The invention relates to application of five antigen proteins in identification and diagnosis of active tuberculosis, provides a diagnostic reagent, and particularly relates to a novel tuberculosis diagnosis method which comprises the following steps of by taking the five antigen proteins P22352, Q9P121, P15151, Q13291 and Q8NDA2 as biomarkers, detecting the content of the five antigen proteins in urine, and taking the quantity value of the specific content as a diagnostic index, and indicating a negative result in the normal value range. And if the concentration of any three or more antigen proteins exceeds or is lower than the normal value range, the result is judged to be positive.

The invention belongs to the technical field of medicine, and particularly relates to IgM (immunoglobulin M) specific protein Rv2915c of mycobacterium tuberculosis and an application of the IgM specific protein Rv2915c. The IgM specific protein Rv2915c and the application aim at providing a new choice for detecting tuberculosis. The protein Rv2915c adopts the technical scheme that an amino acid sequence of the protein Rv2915c of the mycobacterium tuberculosis is shown as SEQ ID No. 1 (sequence identifier number 1). The invention further provides the application of the protein Rv2915c of the mycobacterium tuberculosis in tuberculosis diagnosis. The invention further provides a diagnostic reagent for the tuberculosis. A main active ingredient of the diagnostic reagent is the protein Rv2915c of the mycobacterium tuberculosis. The invention further provides a diagnostic kit for the tuberculosis, which mainly comprises the protein Rv2915c of the mycobacterium tuberculosis. The IgM specific protein Rv2915c of the mycobacterium tuberculosis is applicable to the diagnosis of the tuberculosis.

The invention belongs to the technical field of gene engineering and is related to the technical field of molecular diagnosis of infectious diseases. The invention relates to preparation of three kinds of antigen proteins of Mycobacterium tuberculosis, and application of the three kinds of antigen proteins in preparation of a tuberculosis diagnosis assay kit. The antigen proteins of the Mycobacterium tuberculosis have nucleotide sequences shown as SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:5 in a sequence table, and amino acid sequences encoded by the antigen proteins are shown as SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:6 in the sequence table. Biological experiments indicate that the three kinds of antigen proteins of Mycobacterium tuberculosis can be applied to the preparation of the tuberculosis diagnosis assay kit.

The invention relates to mycobacterium tuberculosis Rv0859 protein as a diagnosis marker in tuberculosis diagnosis. The Rv0859 protein is an amino acid sequence shown in SEQ ID No.1 or a variant of the sequence, which is protein having the same function. The invention also relates to preparation of an antibody for resisting Rv0859 as well as detection application of the anti-Rv0859 antibody as anactive component in tuberculosis diagnosis. A quantitative proteomics method finds that secretion level of the Rv0859 protein is significantly improved under an anaerobic culture condition and the Rv0859 can be used as the marker for diagnosis of tuberculosis; recombination expression in vitro is performed on the Rv0859, recombinant protein is used as an antigen to immunize animals, high-concentration pure anti-Rv0859 antibody is obtained, and the antibody can specifically detect Rv0859 protein of mycobacterium tuberculosis; and on the basis that the effective antibody is obtained, an immunohistochemical detection method with Rv0859 as the detection marker is established, which indicates that a new immunohistochemical detection method for tuberculosis can be established by the anti-Rv0859antibody.

The invention discloses tuberculosis proteins interacting with a human protein NRF1 and applications of the tuberculosis proteins. The invention provides an application of the human protein NRF1 in any one of the following processes of (A1) diagnosing tuberculosis; and (A2) preparing products for the diagnosing the tuberculosis. Screening and identification are carried out by using an MTB mycobacterium tuberculosis proteome chip-based protein-protein interaction experiment to obtain the tuberculosis proteins Rv2239c, Rv0577 and Rv2499c interacting with the human protein NRF1. The tuberculosisproteins can be used for diagnosing the tuberculosis or adjusting the activity of the human protein NRF1.

The invention discloses tuberculoproteins interacting with human proteins and application thereof. The invention provides any one of the applications of human protein SMAD2: (A1), diagnosis of tuberculosis; (A2), preparation of a product for diagnosing tuberculosis. According to the tuberculoprotein interacting with the human protein and the application thereof, by utilizing protein-protein interaction experiment based on MTB mycobacterium tuberculosis aptamer-based proteomics arrays, screening and verification are carried out, and tuberculoproteins Rv2423, Rv3241c, Rv3153, Rv0577, Rv2499c and / or Rv2117 interacting with the human proteins are obtained. The tuberculoproteins can be applied to diagnosis of tuberculosis or regulation of activity of human protein SMAD2.

The invention belongs to the technical field of molecular biological technique, particularly relates to nucleotide mts 90 and the use of a fragment thereof in tuberculosis diagnosis and mainly aims at providing a novel selection for authentication of human mycobacterium tuberculosis and diagnosis of tuberculosis. The sequence of the nucleotide mts 90 is shown as SEQIDNO.1. A reagent for detecting the human mycobacterium tuberculosis is provided. The main component of the reagent is the nucleotide mts 90. A kit for detecting the human mycobacterium tuberculosis is provided and mainly comprises the nucleotide mts 90. The use of the mts 90 in the detection of the human mycobacterium tuberculosis is further provided. The nucleotide mts 90 can be used for authentication of the human mycobacterium tuberculosis and the diagnosis of the tuberculosis.

The invention discloses a gene-deleted recombinant bacillus calmette-guerin vaccine, and belongs to the technical field of zoonosis prevention and treatment. The gene deleted by the strain is a BCG_0349 gene with a nucleotide sequence shown as SEQ ID NO: 1. A homologous exchange substrate containing upstream and downstream homologous arms of the BCG_0349 gene is transduced into a bacillus calmette-guerin vaccine genome in a thermo-sensitive phage transducing mediated homologous recombination mode to knock out the BCG_0349 gene, the strain is successfully constructed, and it is confirmed for the first time that a deleted strain can promote expression and secretion of inflammatory cytokines of the organism and is weakened in toxicity; and specifically, the reduction of the forming ability ofthe soxhlet structure and the reduction of the phenotype and intracellular survival ability of small bacterial colonies are easier for removal of organisms, and the vaccine has good application potential in the related fields of tuberculosis diagnosis of human and animals, vaccine and drug development and the like.

The invention provides a CREB5 gene application, and relates to the preparation of products to distinguish latent tuberculosis infection and active tuberculosis. The preferred products include the products utilizing real-time quantitative PCR or gene chip detection to distinguish the latent tuberculosis infection and the active tuberculosis. According to the experimental results, the expression of the CREB5 gene is obviously higher in the blood of tuberculosis patients than in healthy people or latent infection crowds, and therefore, the CREB5 gene can serve as a special marking gene for the diagnosis of tuberculosis, so as to allow the tuberculosis diagnosis to be more accurate and quicker.

The invention belongs to the technical field of molecular biological technique, particularly relates to nucleotide mts 90 and the use of a fragment thereof in tuberculosis diagnosis and mainly aims at providing a novel selection for authentication of human mycobacterium tuberculosis and diagnosis of tuberculosis. The sequence of the nucleotide mts 90 is shown as SEQIDNO.1. A reagent for detecting the human mycobacterium tuberculosis is provided. The main component of the reagent is the nucleotide mts 90. A kit for detecting the human mycobacterium tuberculosis is provided and mainly comprises the nucleotide mts 90. The use of the mts 90 in the detection of the human mycobacterium tuberculosis is further provided. The nucleotide mts 90 can be used for authentication of the human mycobacterium tuberculosis and the diagnosis of the tuberculosis.

The invention discloses tuberculosis protein interacting with human protein NRF1 and application thereof. The present invention provides the application of human protein NRF1 in any of the following: (A1) diagnosing tuberculosis; (A2) preparing a product for diagnosing tuberculosis. The invention utilizes the protein-protein interaction experiment based on the MTB Mycobacterium tuberculosis proteome chip to screen and identify, and obtain tuberculosis proteins Rv2239c, Rv0577, and Rv2499c interacting with human protein NRF1. The invention can be used for tuberculosis diagnosis or for regulating the activity of human protein NRF1.